within Pharmacolibrary.Drugs.ATC.H;

model H01CB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.69,
    Cl             = 23.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,
    adminCount     = 1,
    Vd             = 0.018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Lanreotide is a long-acting somatostatin analog used in the treatment of acromegaly, gastroenteropancreatic neuroendocrine tumors, and symptoms associated with carcinoid syndrome. It is typically administered as a deep subcutaneous or intramuscular injection. Lanreotide is approved for use in many countries and is a clinically used drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects and patients with acromegaly after single deep subcutaneous injection.</p><h4>References</h4><ol><li><p>Antonijoan, RM, et al., &amp; Montes, M (2004). Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. <i>The Journal of pharmacy and pharmacology</i> 56(4) 471–476. DOI:<a href=&quot;https://doi.org/10.1211/0022357023123&quot;>10.1211/0022357023123</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15099442/&quot;>https://pubmed.ncbi.nlm.nih.gov/15099442</a></p></li><li><p>Hu, M, &amp; Tomlinson, B (2010). Pharmacokinetic evaluation of lanreotide. <i>Expert opinion on drug metabolism &amp; toxicology</i> 6(10) 1301–1312. DOI:<a href=&quot;https://doi.org/10.1517/17425255.2010.513700&quot;>10.1517/17425255.2010.513700</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20716034/&quot;>https://pubmed.ncbi.nlm.nih.gov/20716034</a></p></li><li><p>Kyriakakis, N, et al., &amp; Murray, RD (2014). Lanreotide autogel in acromegaly - a decade on. <i>Expert opinion on pharmacotherapy</i> 15(18) 2681–2692. DOI:<a href=&quot;https://doi.org/10.1517/14656566.2014.970173&quot;>10.1517/14656566.2014.970173</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25307803/&quot;>https://pubmed.ncbi.nlm.nih.gov/25307803</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end H01CB03;
